GPR40 agonists provide efficacy with minimal risk of hypoglycemia; this property is thought to be due to: 1) the glucose dependent nature of GPR40 partial agonist effects on insulin secretion, and 2) that insulin secretion by the beta cell is thought to be the primary driver of glucose lowering with partial agonist therapy [7,8]. The gene discussed is INS; the disease is Hypoglycemia.